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ABSTRACT  
Objective: The short biological half-life (2-3 h) and low bioavailability (50 %) of ranitidine (RAN) following oral administration favor the 
development of a controlled release system. This study was aimed to develop and in vitro evaluate oral sustained-release RAN delivery system 
based on the bacterial nanocellulose material (BNM) produced by Komagataeibacter xylinus (K. xylinus) from selected culture media. 
Methods: BNMs are biosynthesized by K. xylinus in the standard medium (SM) and coconut water (CW). RAN was loaded in BNMs by the absorption 
method. The structural and physicochemical properties of BNMs and BNMs-RAN were evaluated via swelling behavior, FTIR, and FESEM 
techniques. Moreover, the effect of BNMs on RAN release profile and release kinetics was analyzed and evaluated. 
Results: The amount of loaded RAN or entrapment efficacy for BNM-CW is higher than for BNM-SM. The BNM-SM-RAN and BNM-CW-RAN exhibited 
a decreased initial burst release system followed by a prolonged RAN release up to 24 h in relation to the commercial tablets containing RAN. The 
RAN release from these formulations was found higher in the SGF medium than that of in SIF medium. RAN released from these formulations was 
found to follow the Korsmeyer-Peppas model and diffusion sustained drug release mechanism. The sustained release of RAN from BNM-SM-RAN 
was slower than for RAN from BNM-CW-RAN, but the mechanism of sustained RAN release was the same.  
Conclusion: Oral sustained-release RAN delivery system based on BNMs was successfully prepared and evaluated for various in vitro parameters. 
The biopolymers like BNM-SM and BNM-CW could be utilized to develop oral sustained RAN release dosage form. 
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INTRODUCTION 
Bacterial nanocellulose material (BNM), a three-dimensional (3D) 
weblike nanofibrous network structure of cellulose, synthesized in a 
biotechnological process by Komagataeibacter xylinus (K. xylinus) is 
a biodegradable polymer that recently increased considerable 
interest in the biopharmaceutical field, as a result of its unique 
material characteristics, such as extremely high porosity, high 
purity, high mechanical strength, high nanofibers with an ultrafine 
network, high water holding capacity, low toxicity, and 
biocompatibility. Because of its superior properties make it a 
suitable innovative biofabricated material for serving as a potential 
candidate in drug delivery system and also as an excipient [1]. Since 
its nanosized 3D porous networks, including an extremely fine 
cellulose fiber and nanofibrils of 2-4 nm diameter, BNM is expected 
to hold large amounts of active ingredients, resulting in an enormous 
surface area to volume ratio [2]. BNM has already been utilized to 
develop effective drug delivery systems for different drugs or active 
molecules, namely serum albumin [3], berberine [4], octenidine [5], 
polihexanide and povidone-iodine [6], salbutamol [7], famotidine 
and tizanidine [8], curcumin [9], and phenolic [10], with the benefit 
of having a structure of nano-cellulose 3D-networks, thus supporting 
an extended-release of drugs. BNM was used as a delivery system for 
serum albumin [3]. This research showed that freeze-dried 
formulations demonstrated a lower uptake capacity for serum 
albumin than never-dried BNM, which could be explicated by 
changes in the nanofiber network in the time of the freeze-drying 
process. 
Moreover, the biological activity and integrity of serum albumin 
could be retained at the time of the loading and release processes. 
Researchers applied BNM as a carrier for delivery of berberine to 
prolong drug release time as compared to commercial products and 
have potential applications in both oral or transdermal drug delivery 
systems [4]. It was demonstrated that BNM is a potential choice to 
functionalities with the antiseptic drug octenidine. Octenidine 
loaded BNM demonstrated that release profiles were comparable to 
already marketed products. It was investigated that the octenidine 
loaded BNM exhibit a tremendous potential as wound dressing with 
controlled drug delivery [5]. Moreover, BNM was also functionalized 
with the antiseptics povidone-iodine (PI) and polihexanide (PHMB). 
PI-loaded BNM showed a delayed-release compared to PHMB due to 
a high molar drug mass and structural changes induced by PI 
insertion into BNM that also increased the compressive strength of 
BNM samples [6]. The other research confirmed that BNM is a 
promising choice to gelatin capsules with both fast and slow-release 
properties of the drug depending upon the constitutions of the 
enclosed materials [7]. The researchers claimed that BNM can be 
used as a matrix for loading with model drugs (tizanidine is a highly 
water-soluble drug, famotidine is poorly water-soluble) and 
assessed as a single excipient based drug delivery system [8]. 
Ranitidine (RAN) is N-[2-[[[5-[(dimethylamino) methyl]-2-furanyl] 
methyl]thio]ethyl]-N-methyl-2-nitro-1,1-ethenediamine. RAN is an 
antisecretory drug with H2 antagonist action useful in treating gastric 
and duodenal disorders [11-20]. The adult oral dosage, frequency of 
RAN is 150 mg twice per d or 300 mg once per d. A conventional dose 
of 150 mg can inhibit gastric acid secretion up to 5 h but not up to 10 h. 
An alternative dose of 300 mg leads to plasma fluctuations [18, 20, 21]. 
The reason for multiple dosing frequencies or high dose is due to its 
short biological half-life (2-3 h) and low bioavailability (50 %) [13, 15, 
18, 21]. In order to overcome these problems, an attempt was made to 
develop oral sustained-release drug delivery systems for RAN. In vitro 
drug release studies of RAN microspheres showed a controlled release 
of 11 h with Eudragit RL-100 [11]. The data obtained in this study thus 
suggest that a microparticulate floating dosage form of an anti-ulcer 
drug can be successfully designed to give controlled RAN delivery and 
improved oral bioavailability. Floating in situ gel of RAN using natural 
polymers like sodium alginate and pectin and calcium carbonate as a 
cross-linking agent was formulated and evaluated [13]. It was shown 
that the sustained release of RAN can be achieved by in situ gel along 
with good floating properties. RAN buccal films of Sterculia foetida 
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gum in combination with carbopol 934P have shown very good 
physical stability, excellent mucoadhesive strength, good stability and 
prolonged drug release [14]. Tripolyphosphate (TPP)-crosslinked 
chitosan (CH)/poly (ethylene oxide) (PEO) electrospun nanofibrous 
mats as a floating gastro-retentive delivery system for RAN were 
prepared and evaluated [19]. Based on the obtained results in this 
study, TPP-crosslinked CH/PEO nanofibrous mats lower initial burst 
release and it was showing a prolonged release profile for the RAN 
from the TPP-crosslinked CH/PEO-RAN electrospun nanofibrous mats. 
The aim of the present work was to develop and evaluate oral 
sustained-release RAN delivery system based on BNM produced by K. 
xylinus in selected culture media. 
MATERIALS AND METHODS 
Materials 
The bacterial strain of Komagataeibacter xylinus (ATCC 23767) was 
purchased from the Biological Resource Center, National Institute of 
Technology and Evaluation, Japan. 
Ranitidine 99.5% and yeast extract were purchased from Sigma-
Aldrich (USA). Peptone was purchased from ECHA (European Union) 
and other chemicals used in the analysis were purchased from 
China. Commercial tablets containing RAN (TAB-RAN) were 
purchased from the local market. All the analytical grade chemicals 
and solvents were used as received without additional refinement 
and analysis.  
Methods 
Biosynthesis of bacterial nanocellulose material  
Bacterial nanocellulose material (BNM) was produced by 
Komagataeibacter xylinus (K. xylinus) (ATCC 23767) using the 
method of static culture in two selected liquid media [3-10, 23] 
which were composed of the standard medium (SM) and coconut 
water (CW). Firstly, glucose (20 g), peptone (5 g), diammonium 
phosphate (2.7 g), yeast extract (5 g), citric acid (1.15 g) and double-
distilled water (1000 ml) were used in SM. Secondly, glucose (20 g), 
peptone (10 g), diammonium phosphate (0.5 g), ammonium sulfate 
(0.5 g) and coconut water (1000 ml) were used in CW. The selected 
culture media were sterilized at 121 °C for 20 min.  
For pre-culture, K. xylinus (ATCC 23767) powder was activated in a 
100-ml flask containing 50 ml of pre-culture medium such as glucose 
(100 g), agar (15 g), CaCO3 (20 g), yeast extract (10 g) and distilled 
water (1000 ml), initial pH of 6.8. It was incubated at 150 rpm 
shaking and 28 °C for 2 d using an orbital shaker (Lab companion, 
SKF-2075, Korea). The activated bacteria were then cultured for 2 d 
in a 250-ml shaker bottle containing 100 ml SM medium to increase 
the number of bacteria. After that the pre-culture (10 %) was 
transferred to two selected liquid media and incubated under 
stationary conditions at 28 °C for a defined time period (usually 12-
15 d) for the production of the BNM with the desired thickness (1 
cm). BNM was rinsed thoroughly with distilled water and treated 
with 0.3 M NaOH solution in an autoclave (Hirayama, Japan) at 121 
°C for 20 min to eliminate any remnants of bacterial colonies. The 
BNM was again thoroughly rinsed with distilled water till reaching 
neutral pH and stored at 4 °C for further use [4, 7, 8]. 
Preparation and evaluation of RAN loading and entrapment 
efficiency of BNM 
The BNM was fabricated with the help of a locally designed circular-
shaped disc fabricator (1.5 cm diameter) [8]. After partial removal of 
the water, the BNMs with the diameter 1.5 cm and thickness 1 cm 
created from culture media (SM, CW) were added a RAN solution by 
using absorption method in the optimized conditions (drug 
concentration: 250 mg/ml; temperature: 50 °C; shaking speed: 140 
rpm; time of drug absorption: 150 min). The concentration of the 
RAN remaining in the loading solution was determined using a UV-
Vis spectrophotometer (UV-Vis 2450, Shimadzu, Japan) at 314 nm 
[18]. A calibration curve of RAN solution in HCl 0.1N within the 
concentration range of 1 µg/ml to 6 µg/ml was used for determining 
RAN loadings in BNMs samples. The amount of loaded RAN into 
BNM was calculated according to formula 1 [3, 6, 22].  
mab = m1 − m2 (1) 
Where mab is the amount of RAN that is loaded into the BNM (actual 
amount of drug); m1 is the initial RAN dose in solution (theoretical 
amount of drug); m2 is the excessive amount of RAN existing in the 
solution after a certain period of time BNM absorbs the RAN. The 
RAN entrapment efficiency (EE) of BNMs was calculated according 
to formula 2.  




Morphological analysis  
The surface topography and morphology of the BNMs and BNMs-
RAN were visualized by a field emission scanning electron 
microscopy (FESEM, S-4800, Hitachi, Japan). The samples heat at 40 
°C in 20 min, cover, then a thin platinum layer and put into the 
sample chamber [3, 4, 8, 10]. 
Fourier transform infrared spectroscopy analysis  
Fourier transform infrared (FTIR) analysis was performed to 
characterize the presence of specific chemical groups to confirm the 
presence of RAN in BNMs using FTIR Affinity-1S (Shimadru, Japan). 
Spectra for all samples is directly measured by Reflectometry in 20 °C, 
moisture 40-43 %. The samples were scanned in the IR range from 
400 to 4000 cm−1 [14, 19]. Interaction between the components, if any, 
was indicated by either producing additional peaks or absence of 
characteristic peak corresponding to RAN and BNMs. 
Swelling behavior analysis 
To study the swelling behavior of BNMs-RAN, the swelling degree 
(amount of water uptake) was measured by immersion of the known 
weight dried samples in test tubes, including 30 ml simulated 
gastrointestinal fluid (SGF, pH 1.2; and SIF, pH 6.8) at 37 °C for 24 h. 
Then, the water on the surfaces of the samples should be eliminated 
with filter paper and the specimens are to be weighed in wet 
condition. The swelling ratio (SR) of test samples was measured 





Where Md is the weight of dried sample and Mw is the weight of 
swollen sample. 
In vitro RAN release analysis 
The in vitro RAN release analysis from BNMs-RAN (BNM-SM-RAN, 
BNM-CW-RAN) and RAN tablets were performed in simulated 
gastrointestinal fluid (SGF, pH 1.2; and SIF, pH 6.8) for 24 h [19]. The 
dissolution test apparatus fixed with eight rotating paddles (Agilent 
708-DS Dissolution Apparatus, Malaysia) was used. Test samples 
(BNM-SM-RAN, BNM-CW-RAN and RAN tablets) were placed in 900 ml 
of the same SGF or SIF medium and kept at 37±0.1 °C under a stirring 
rate of 50 rpm. At known time intervals (0, 0.5, 1, 2, 4, 6, 8, 12, and 24 
h), 5 ml aliquots of the solution were withdrawn from the release 
medium and replaced with the fresh solution to keep the total volume 
900 ml. The withdrawn solution was applied to determine the RAN of 
release medium using a UV-Vis spectrophotometer (UV-Vis 2450, 
Shimadzu, Japan) at the wavelength of 315 nm for buffer solution with 
pH 1.2; 314 nm for buffer solution with pH 6.8. A calibration curve for 
RAN was plotted against its concentration in buffer solutions (pH 1.2, 
6.8) within the concentration range of 1 µg/ml to 6 µg/ml and was 
regressed into linear line corresponding to the regression equation: y 
= 0.0047x+0.0298 (R2 = 0.9998) for pH 1.2 and y = 0.0045x+0.0473 
(R2 = 0.9997) for pH 6.8 (where y is the absorbance of the RAN 
solution and x is the concentration of the RAN). The cumulative release 
ratio (CR) of RAN from the samples was calculated based on the 








Where Ct is the concentration of RAN in the buffer solutions at t time, V1 
is the volume of buffer solution at different pH values (900 ml, and pH 
1.2, 6.8), n is the number of samples removed from the release medium, 
V2 = 5 ml, and m is the initial total amount of RAN in the samples. 
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Kinetics and mechanism of drug release 
In vitro drug release data were analyzed by using different kinetic 
models to find the mechanism of drug release. The values of various 
kinetic models were calculated with the help of DDSolver, an add-in 
extension for Microsoft Excel [24]. The mechanism of RAN release 
from the BNMs-RAN was calculated by fitting release data with 
different release kinetic models such as zero order, first order, 
Higuchi's and Korsmeyer-Peppas equations. Data of release kinetics, 
such as of kinetic rate constant (k), correlation coefficient (R2) and 
release exponent (n) were calculated for the determination of the 
best fit model [4, 7, 11, 13, 16]. 
Data analysis and statistics  
All the results obtained in the above-mentioned experiments are 
stated as mean±SD (Standard deviation) and are shown in the fig. 
and tables. The difference between the groups was evaluated by the 
one-way ANOVA test, using the Analysis ToolPak in Microsoft Excel 
2010 and DDSolver (an add-in extension for Microsoft Excel) [24]. 
The differences are considered to be statistically significant when 
the P values are less than 0.05. All experiments were repeated at 
least three times. 
RESULTS AND DISCUSSION 
Preparation of BNMs and BNMs-RAN 
Regarding cost-effective BNM for bio-phamercutical applications, 
the BNM in the present study produced by K. xylinus was compared 
in a low-cost substrate medium (CW) and a standard medium (SM). 
After the activated bacteria, K. xylinus was cultured in the nutrient 
media (SM, CW) [9] from 12 to 15 d at 28 °C for producing BNM with 
the desired thickness (1 cm). The results showed that the time for 
producing BNM with a thickness of 1 cm was longer in CW (15 d) 
than in SM (12 d) under the same conditions. Therefore, SM is a 
better medium than CW for BNM production. However, the SM is 
expensive due to yeast extract used as a key nitrogen source. In this 
work, BNM was successfully produced by K. xylinus from both 
fermentative media containing SM and CW under static conditions. 
The BNMs with a diameter of 1.5 cm and a thickness of 1 cm (similar 
to the size of the commercially available RAN tablets) were 
fabricated with the help of a locally designed circular-shaped disc 
fabricator (1.5 cm diameter) [8]. After partial removal of the water, 
the BNMs produced from selected media (SM, CW) were added a 
RAN solution by using absorption method in the optimized conditions 
(drug concentration: 250 mg/ml; temperature: 50 °C; shaking speed: 
140 rpm; time of drug absorption: 150 min). At the end of the 
experiment, the sample was removed from the absorbent solution to 
measure the OD (optical density), based on the RAN's calibration 
curve to calculate the amount of loaded RAN and the RAN entrapment 
efficiency of the BNMs. The results in table 1 showed that there was a 
significant difference in the amount of loaded RAN (mg) or RAN 
entrapment efficacy (%) of BNMs, which were produced from different 
culture media (SM, CW). The BNM-CW showed higher drug loading 
and entrapment efficiency, probably due to the difference of the 
density and porous fibrous network of BNM produced in selected 
media (SM, CW), facilitating the diffusion of the drug into BNM [4, 8]. 
Characterization of BNMs and BNMs-RAN  
BNM is a nanofibrillar form of cellulose with a porous structure and 
high water-holding capacity. The swelling behavior would possibly 
represent the relative evaluation of the entanglement and the 
compression between the nanofibers [19]. The swelling ratio of 
BNMs-RAN was evaluated in the simulated gastrointestinal 
conditions (SGF, pH 1.2; and SIF, pH 6.8). The results of the swelling 
profile of BNMs-RAN are shown in table 2. 
  
Table 1: Evaluation of RAN loading and entrapment efficiency of BNMs (All values are expressed as mean±SD, n = 3) 
BNM types RAN loading (mg) Entrapment efficiency (%) 
BNM-SM 152.33±4.04 60.93±1.62 
BNM-CW 167.00±4.58 66.80±1.83 
 
Table 2: Evaluation of the swelling profile of BNMs-RAN in SGF or SIF at 37 °C (All values are expressed as mean±SD, n = 3) 
Formulations SGF (pH 1.2) (%) SIF (pH 6.8) (%) 
BNM-SM-RAN 74.67±2.52 60.33±3.21 
BNM-CW-RAN 90.67±3.06 81.00±2.65 
 
As listed in table 2, the swelling behavior results show that this 
parameter of BNMs-RAN occurring at pH 1.2 is higher than in pH 6.8 
medium. The result of the present study is also supported by those 
of a previous study in which indicating fiber expansion of BNM in 
treatment with acid [4]. While the BNM-SM-RAN can absorb 
74.67±2.52 % of the water in SGF or 60.33±3.21 % of the water in 
SIF, BNM-CW-RAN has a water uptake capacity of 90.67±3.06 % in 
SGF or 81.00±2.65 in SIF. These values demonstrate that the low 
density and high porous fibrous network of BNM-CW consequence 
the raise of the distance between these nanofibers, and the increased 
penetration of water into nanofibers. 
The nanoscale fibril network of BNM produced by K. xylinus in SM 
and CW was visualized under FESEM. The FESEM images in fig. 1 
showed that the randomly oriented and densely packed network of 
ultrafine fibrils was observed in the BNM synthesized by K. xylinus in 
SM and CW. As a result, FESEM images of the cross-section and 
surface view of BNM showed a clear, well organized, densely 
arranged and interconnected porous nanofibrous network. The 
results are in agreement with the previous studies [3, 4, 7, 8]. 
It is clearly observed that FESEM analysis of cross-sections of the 
RAN-loaded BNM in comparison with an unloaded BNM sample 
showed that the structure of samples was not affected throughout 
the different processes in terms of the fiber network. A tendency of 
an increase in the size of pore areas due to further swelling 
processes during the loading procedure could be observed. BNM-SM 
showed slightly higher fiber diameters and lower pore sizes than 
BNM-CW, probably caused by a decrease in fiber distances and 
partial assembly of adjacent polymer fibers.  
FTIR spectra of RAN, BNM-SM, BNM-CW, BNM-SM-RAN, and BNM-
CW-RAN were recorded and are presented in the fig. 2, 3, 4, 5, and 6. 
The study of the FTIR spectra of RAN has shown in fig. 2 
demonstrated that a band at 3504 cm-1 connected to the 
overlapped stretching vibrations of OH and NH2 functional groups. 
The absorption peaks appeared at 2938, 1633 and 1408 cm-1 were 
imputed to the C-H stretching, amide bending and -CH2 bending 
vibrations, respectively [19]. The FTIR spectra of BNM in this 
study displayed the typical features of cellulosic substrates with 
intense bands around 3341, 2894, 1107 and 612 cm-1, associated 
with the vibrations of the -OH, C-H, C-O-C and -CH2- groups, 
respectively [4, 17]. 
The obtained data revealed that in the RAN loaded BNM, no additional 
peaks attributable to the formation of a complex appeared, but 
variations in the relative intensities of the characteristic peaks for BNM 
and the RAN can be observed. It has been observed that the absorption 
bands of both RAN and RAN with BNMs remaining the same. It was 
concluded that no such interaction between the RAN and BNMs was 
occurring. Moreover, the appearance of specific absorption peaks 
associated with functional groups of BNM and RAN (fig. 5 and 6) 
revealed the successful RAN loading into BNM without any chemical 
alteration in the structure of the RAN and BNM. 
Evaluation of in vitro drug release 
The release profiles of RAN from the commercial tablets containing 
RAN (TAB-RAN), BNM-SM-RAN and BNM-CW-RAN were investigated 
in the simulated gastrointestinal conditions (SGF, pH 1.2 and SIF, pH 
6.8), and obtained results are shown in fig. 7 and fig. 8. 
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Fig. 1: Morphological characterization of BNMs and BNMs-RAN. FESEM images of BNM-SM on cross-section view (A) and surface view (E), 
BNM-SM-RAN on cross-section view (B) and surface view (F), BNM-CW on cross-section view (C) and surface view (G), BNM-CW-RAN on 
cross-section view (D) and surface view (H) 
 
 
Fig. 2: FTIR spectra for ranitidine (RAN) 
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Fig. 3: FTIR spectra for BNM-SM 
 
 
Fig. 4: FTIR spectra for BNM-CW 
 
 
Fig. 5: FTIR spectra for BNM-SM-RAN 
 
 
Fig. 6: FTIR spectra for BNM-CW-RAN 
Nguyen et al. 




Fig. 7: In vitro RAN release profiles for BNMs-RAN and TAB-RAN in SGF at 37 °C (Results are expressed as mean±SD, n=3) 
 
 
Fig. 8: In vitro RAN release profiles for BNMs-RAN and TAB-RAN in SIF at 37 °C (Results are expressed as mean±SD, n=3) 
 
As it could be observed from fig. 7 and fig. 8, the commercial tablets 
containing RAN (TAB-RAN) in the simulated gastrointestinal 
conditions exhibited a burst RAN released in a short time period 
because of the rapid dissolution of RAN in the simulated gastric 
conditions [19]. The in vitro release profiles in all experimental 
simulated gastrointestinal conditions showed a significant difference 
(P<0.05) in the release of RAN from BNMs-RAN, suggesting pH-
dependent release. However, the TAB-RAN showed a distinct release 
pattern when compared to the release of RAN from BNMs-RAN. 
More than 90% of the RAN was released from the TAB-RAN in the 
first 2-4 h of study at all two simulated pH media. As a result, most of 
the drug will reach the blood for systemic action after absorption 
through the gastrointestinal tract that may lead to fluctuations in 
plasma drug levels and undesirable side effects. However, a high 
initial burst RAN release from the BNMs-RAN could not be seen in 
the initial hours. A key reason for the sustained drug release might 
have imputed to the 3D weblike nanofibrous network structure of 
BNM, which limited the movability the nanofibers, resulted in the 
reduction of the initial burst RAN release from BNMs-RAN. As the 
results showed in fig. 7 and fig. 8, the content and the rate of RAN 
released from the BNMs-RAN at pH 6.8 are lower than those at pH 
1.2. BNM had a pH-responsive feature that has been demonstrated in 
a previous study [4]. The higher swelling ratio was attained when 
the entrance of the swelling fluid into the nanofibers was facilitated. 
The more the nanofibers swell, the more the fluid diffuse within the 
nanofibers and the more the trapped drug would be released [19].  
Moreover, the RAN release from BNM-SM-RAN in both SGF and SIF 
medium was found slower from BNM-CW-RAN. The nanofiber 
density and extremely porous network of BNM-CW could be the 
possible reason for the faster RAN release. Swelling behavior studies 
and FESEM analysis confirm this hypothesis. 
Kinetics and mechanism of drug release 
Drug release profiles of the BNMs-RAN and TAB-RAN were fitted 
into zero-order, first-order, Higuchi's and Korsmeyer-Peppas models 
to describe the kinetic behavior of the drug release mechanism from 
the formulations, the most suitable being the one that best fits the 
experimental results. The correlation coefficients for the different 
drug release kinetic models are shown in tables 3 and 4. In both SGF 
and SIF medium, the BNM-SM-RAN and BNM-CW-RAN followed 
Korsmeyer-Peppas kinetics with high linearity, whereas the TAB-
RAN followed first-order kinetics. To confirm the diffusion 
mechanism, the data were fitted into the Korsmeyer-Peppas model. 
The use of Korsmeyer-Peppas equation, the interpretation of release 
exponent (n) values, gives an insight into the release mechanisms. 
According to the Korsmeyer-Peppas model, an amount of 
n<0.5/0.45/0.43 for a slab/cylinder/sphere indicates a diffusion 
controlled drug release process [4, 13]. As the results showed in 
tables 3 and 4, all the n values were less than 0.5, so Fickian diffusion 
is the predominant drug release mechanism. These findings are in 
agreement with previous studies reported in the literature, whereby 
drug release follows Ritger-Peppas kinetics from through the 
polymeric porous three-dimensional matrix [4]. 
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Table 3: Values of correlation coefficient (R2), the kinetic rate constant (k), and release exponent (n) from BNMs-RAN and TAB-RAN in SGF 
at 37 °C 
Formulations Zero-order First-order Higuchi Korsmeyer-Peppas 
R2 k R2 k R2 k R2 k n 
BNM-SM-RAN 0.2436 5.23 0.8861 0.23 0.7579 22.88 0.9381 37.67 0.29 
BNM-CW-RAN 0.6666 5.88 0.9197 0.41 0.6059 26.21 0.9435 48.63 0.24 
TAB-RAN 0.7795 21.77 0.9988 1.21 0.9278 49.13 0.9843 67.28 0.24 
 
Table 4: Values of correlation coefficient (R2), the kinetic rate constant (k), and release exponent (n) from BNMs-RAN and TAB-RAN in SIF 
at 37 °C 
Formulations Zero-order First-order Higuchi Korsmeyer-Peppas 
R2 k R2 k R2 k R2 k n 
BNM-SM-RAN 0.5613 3.01 0.8474 0.08 0.6654 13.25 0.9703 24.04 0.25 
BNM-CW-RAN 0.1180 4.21 0.7079 0.12 0.8073 18.26 0.9501 28.84 0.31 
TAB-RAN 0.7893 11.53 0.9718 0.73 0.7633 35.59 0.9592 55.60 0.26 
Although the release rate for RAN from BNM-SM-RAN was slower than for RAN from BNM-CW-RAN in both SGF and SIF medium, the drug release 
mechanism was the same. 
 
CONCLUSION 
Oral sustained-release RAN delivery system based on BNMs was 
successfully developed and evaluated for various in vitro 
parameters. The amount of loaded RAN or entrapment efficacy for 
BNM-CW is higher than for BNM-SM. The BNM-SM-RAN and BNM-
CW-RAN exhibited a decreased initial burst release system followed 
by a prolonged RAN release up to 24 h in relation to the commercial 
tablets containing RAN. The RAN release from these formulations 
was found higher in the SGF medium than that of in SIF medium. 
RAN released from these formulations was found to follow the 
Korsmeyer-Peppas model and diffusion sustained drug release 
mechanism. The sustained release of RAN from BNM-SM-RAN was 
slower than for RAN from BNM-CW-RAN, but the mechanism of 
sustained RAN release was the same. Based on the obtained results, 
the biopolymers like BNM-SM and BNM-CW could be utilized to 
develop oral sustained RAN release dosage form. 
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